Resources

Evaluation of huCART19-IL18 Manufactured Using Synecta CDNP Technology to Improve CAR-T Yield and Consistency in Cohort D of an Ongoing Phase I Study (NCT04684563)

Cell-Derived Nanoparticle Platform Offers Versatile Use of Membrane-Bound and Soluble Cytokines for Rapid and Efficient CAR-T Cell Production

Break The Cell Therapy Manufacturing Bottleneck With Day-0 Transduction, Day-3 Harvest

Revolutionizing CAR-T Manufacturing: A New Era in T Cell Expansion

Cell-Derived Nanoparticles (CDNPs) Simplify, Accelerate, and Enhance the Consistency of Manufactured CAR-T Cells